Sunlight sits on both sides of the ledger, and the two sides are known with very different confidence. Ultraviolet light causes skin cancer — that part is settled, resting on a randomized sunscreen trial and a 57-study meta-analysis. Pulling the other way is a stranger finding: in one long Swedish cohort, the women who avoided the sun died sooner, and not only of skin cancers. So the practical question is not sun: good or bad? but a trade-off you can act on. Avoiding sunburn is the firm move, and it costs almost nothing.
Whether actively seeking sun buys extra years is genuinely unsettled — that signal is a single observational study, wide open to the likelihood that sick, frail people simply stay indoors. The vitamin-D pill most people reach for to sidestep the whole question does not reproduce the benefit in trials. Where the balance lands depends on your skin and your latitude: for fair skin under strong year-round sun, skin-cancer risk dominates; for darker skin at high latitude, the same relative risk is a far smaller absolute one.
For melanoma, the pattern of exposure matters more than the total dose
The single most useful fact about sun and skin cancer is that “sun exposure” is not one exposure. Short, intense, burning bouts on pale skin drive melanoma; steady day-in-day-out exposure does not. Gandini’s meta-analysis of 57 studies (38,671 melanoma cases) sorts the risk cleanly by pattern (Gandini et al., 2005):
| Exposure pattern | Pooled RR (highest vs lowest) | 95% CI | Direction |
|---|---|---|---|
| Sunburn history | 2.03 | 1.73-2.37 | strong risk |
| Intermittent (recreational / holiday) | 1.61 | 1.31-1.99 | risk |
| Total sun (all kinds) | 1.34 | 1.02-1.77 | weak risk |
| Chronic / occupational | 0.95 | 0.87-1.04 | null |
A history of sunburn carries the largest and most actionable signal, and it is worse the earlier it happens — childhood sunburn RR 2.24, and the risk climbs with latitude (RR 2.54 at 50 degrees or higher) (Gandini et al., 2005). On the 19 studies that measured both patterns directly, intermittent exposure (RR 1.46) beat chronic (RR 1.09), P=0.015, so the split is not an artifact of comparing different study sets (Gandini et al., 2005). The mechanism fits: an intense burst hits unprotected skin and reaches the melanocytes, while regular exposure on tanned, thickened skin is largely blocked at the surface.
One reading to avoid: the near-null for chronic exposure does not mean outdoor work protects you. Gandini is explicit that the comparison group is confounded (Gandini et al., 2005):
«It is important to stress that it is unlikely that the inverse association with chronic sun exposure means that occupational sun exposure protects against melanoma … The reference category for occupational sun exposure is low continuous pattern sun exposure, which will include people with high intermittent pattern sun exposure, as well as people with low sun exposure of any kind.»
Basal and squamous cell carcinomas — the common “keratinocyte” skin cancers — also rise with sun exposure (Lindqvist et al., 2016), but they are rarely fatal and are usually treated locally, so melanoma is the lethal endpoint the evidence below quantifies. (The exact keratinocyte-cancer effect sizes are not held in the fabric — a named gap.)
Sunscreen is the one protective move tested in a randomized trial
Everything above is observational. The single randomized test of sun protection against melanoma is the Nambour Skin Cancer Prevention Trial: 1,621 fair-skinned Australian adults randomized in 1992 to daily broad-spectrum SPF-16 sunscreen or discretionary use, followed about 15 years (Green et al., 2011). Over that span, 11 of 812 in the daily group developed melanoma versus 22 of 809 in the discretionary group (Green et al., 2011) — roughly 1.3% versus 2.7%, an absolute gap near 1.4 percentage points in a sun-drenched, fair-skinned population:
«Ten years after trial cessation, 11 new primary melanomas had been identified in the daily sunscreen group, and 22 had been identified in the discretionary group … (hazard ratio [HR], 0.50; 95% CI, 0.24 to 1.02; P .051). The reduction in invasive melanomas was substantial (n 3 in active v 11 in control group; HR, 0.27; 95% CI, 0.08 to 0.97) compared with that for preinvasive melanomas (HR, 0.73; 95% CI, 0.29 to 1.81).»
Read this with its limits. The all-melanoma result (HR 0.50) was borderline (P=.051); the eye-catching 73% cut in invasive melanoma (HR 0.27) rests on 3 versus 11 cases and the authors label it exploratory; melanoma was a secondary endpoint; and the lead author disclosed L’Oreal research funding. Two things nonetheless hold up. It is the only trial of its kind, and the sunscreen and discretionary groups spent similar time outdoors — so the protection came from blocking UV, not from the sunscreen group avoiding the sun (Green et al., 2011). The authors’ own summary is deliberately hedged: «Melanoma may be preventable by regular sunscreen use in adults.»
The “sun-avoiders die sooner” signal is real but weakly grounded
Now the counterweight. Lindqvist followed 29,518 Swedish women for 20 years and found that the ones who avoided the sun did not just get less skin cancer — they died earlier. Compared with the highest-exposure group, sun avoiders ran roughly 1.7 to 2 times the all-cause mortality (categorical HR about 0.6 for the highest group; 0.7 once exercise was added in a subset), the gap widened dose-dependently for cardiovascular death (subdistribution HR 1.5 then 2.3 across exposure levels), and avoiders lost an estimated 0.6 to 2.1 years of life expectancy (Lindqvist et al., 2016). The authors put the magnitude in a startling frame:
«Nonsmokers who avoided sun exposure had a life expectancy similar to smokers in the highest sun exposure group, indicating that avoidance of sun exposure is a risk factor for death of a similar magnitude as smoking.»
That comparison is a life-expectancy contrast drawn within this one cohort, not a validated causal equivalence between sun avoidance and smoking — treat it as a vivid illustration, not an established fact.
The whole arm sits well below the melanoma evidence in strength, for one concrete reason: the people who avoided the sun were different in ways that also shorten life. They were much older (58.7% aged 55-64 versus 13.9% of the high-exposure group), poorer (45.7% low-income versus 14.8%), far more likely to be chronically ill (20.4% comorbid versus 6.7%), and less active (Lindqvist et al., 2016). Sick and frail people stay indoors, which is exactly the reverse-causation and confounding-by-frailty that inflates this kind of protective signal (see The U-Shaped Association Artifact). The association did survive adjustment for age, smoking, education, income, comorbidity and exercise, which raises it above a naive correlation — but the authors concede they cannot close the gap:
«First, it is not possible to differentiate between active sun exposure habits and a healthy lifestyle, and secondly, the results are of an observational nature; therefore, a causal link cannot be proven.»
There is no randomized trial on this arm, and no second cohort to confirm it. It belongs in the open-question column: a plausible, adjustment-robust, but unreplicated observational signal from a single population of Swedish women — neither taken at face value nor dismissed.
There is also a trap in reconciling the two arms. It is tempting to say melanoma comes from burning while the mortality benefit comes from gentle regular sun, so a single strategy captures both. Lindqvist’s data do not support that escape. The sun-exposure score was built entirely from recreational, intermittent habits — summer sunbathing, winter and mountain sunbathing, holidays abroad, and tanning-bed use (Lindqvist et al., 2016). That is precisely the intermittent pattern Gandini flags as melanoma-causing. So the same sun-seeking behaviour raises melanoma in one study and tracks lower mortality in the other: a genuine trade-off on one habit, not two habits that conveniently separate.
A vitamin-D pill does not stand in for sunlight
The obvious mechanism to explain a sun-mortality benefit is vitamin D, and it is the reason people take a supplement instead of going outside. The supplement trials do not cooperate. VITAL randomized 25,871 US adults — a population that was largely vitamin-D replete — to 2000 IU/day of vitamin D, and found no effect on its two primary endpoints: cancer HR 0.96 (95% CI 0.88-1.06) and major cardiovascular events HR 0.97 (0.85-1.12) (Manson et al., 2019). Pooling the whole trial literature tells the same story for death itself: across 50 RCTs and 74,655 participants (mostly replete), vitamin D did not move all-cause mortality (Zhang et al., 2019):
«Vitamin D supplementation was not associated with all cause mortality (risk ratio 0.98, 95% confidence interval 0.95 to 1.02, I2=0%), cardiovascular mortality (0.98, 0.88 to 1.08, 0%), or non-cancer, non-cardiovascular mortality (1.05, 0.93 to 1.18, 0%).»
In fairness to the mechanism, that same analysis found a 15% reduction in cancer death (RR 0.85, 0.74-0.97) — one positive secondary endpoint, GRADE-high on the all-cause null. But the headline outcome, all-cause mortality, did not budge. The logic is straightforward: if sunlight’s apparent survival benefit ran through vitamin D, a vitamin-D pill should reproduce it, and it does not. So whatever the sun is doing here, oral vitamin D is not a substitute for it . A supplement is the transmission test a surrogate has to pass to earn its place, and vitamin D fails it here (see Surrogate Outcomes). Those same trials read as an enhancement null — no benefit from adding more to an already-replete population (see Deficiency Repletion vs Enhancement).
If the mortality arm is causal at all, the more likely routes are non-vitamin-D UV pathways — skin nitric oxide lowering blood pressure, melatonin, beta-endorphin — which Lindqvist raises and which no supplement can deliver (Lindqvist et al., 2016). Lindqvist puts it plainly: «Vitamin D levels might be just a marker of sun exposure.»
What tips the balance: your skin and your latitude
The net of a firm harm against a weak possible benefit is not the same for everyone, and most of the movement comes from one lever — your baseline melanoma risk, which is set mainly by skin type and ambient UV. This is the safe kind of stratification: the relative risks above stay roughly constant, but the same relative risk becomes a much bigger or smaller absolute risk as the baseline shifts.
- Fair skin (Fitzpatrick I-II) under high year-round UV — Queensland, the sunbelt, a UV index at or above 6 most of the year. Melanoma baseline risk is high, so the harm arm dominates and protection is the clear call. This is the population Nambour was run in, where daily sunscreen measurably cut melanoma.
- Darker skin, or high latitude with low UV — Sweden’s UV index stays below 3 for eight or nine months. Melanoma baseline risk is far lower, so the same relative harm is a much smaller absolute harm, and the weak, confounded mortality signal carries relatively more weight. Lindqvist argues that blanket year-round sun-avoidance advice may not serve people in a low-UV, high-latitude country — a baseline-risk argument, not a vitamin-D one.
Two honest caveats sit on this. The “regular non-burning exposure” that would, in theory, capture a mortality benefit without the melanoma cost is a hypothesis, because it is not what Lindqvist measured — its recreational-habit score cannot separate gentle habitual sun from holiday burning. And sunscreen is only a partial escape: in Nambour it cut melanoma without cutting outdoor time, but Lindqvist warns against reading sunblock as a licence to bake for longer. Cosmetic effects — wrinkling and photo-ageing from cumulative UV — are real, but they sit off the health axis; note them, weigh them yourself, and do not let them stand in for a cancer or mortality argument.
What to do
- Don’t burn — this is the big lever, and it is nearly free. Sunburn carries the largest melanoma signal (RR ~2), childhood sunburn worst of all. Protecting children and avoiding holiday-type burning bouts buys most of the achievable risk reduction.
- Use sunscreen and cover up in strong sun. It is the one protective step shown in a randomized trial to lower melanoma, and it worked without anyone spending less time outside.
- Do not treat a vitamin-D pill as a stand-in for sunlight. Supplement trials in replete people show no all-cause mortality benefit, so the pill does not buy whatever the sun’s signal might represent. Repletion of a genuine deficiency is a separate question (see Deficiency Repletion vs Enhancement).
- Let your skin and latitude set the dial. Fair skin under strong year-round sun: prioritize protection. Darker skin at high latitude: strict year-round avoidance is not clearly warranted, and the modest sun most people get is not the melanoma driver — burning is.
- Don’t chase the “sun makes you live longer” headline. It is one unreplicated, confounded observational study; the sunburn-melanoma link is far firmer, and the two attach to the same recreational habit.
A related but distinct question — deliberate heat exposure (sauna) and cardiovascular risk — is a different exposure from UV and is treated separately in Sauna Bathing and Cardiovascular Mortality; do not read a sauna finding as a sunlight finding.
The loop is open. No source here measured the net effect of a sun-seeking versus a sun-avoiding strategy on all-cause mortality in a randomized trial. The melanoma harm is anchored on an RCT and a gold-standard meta-analysis; the mortality benefit is a single observational cohort; the vitamin-D null is high-certainty but only tells us what does not mediate the signal. This deliverable grades the coherence of that evidence, not whether acting on it makes any individual better off.
Evidence box
Question ’What does the evidence show about sun / UV exposure across its patient-important outcomes — skin cancer (melanoma and keratinocyte cancers) against the all-cause-mortality and vitamin-D signals — how does each effect vary with dose, skin type, and latitude, and how should a person weigh the trade-off?‘ Evidence included 5 sources — 2 gold, 3 high Overall certainty Low-moderate (see Rating Certainty of Evidence) Source-selection note All sources are gold or high tier. Last updated 2026-09-09 · Independently reviewed: No · Full edit history